Global Cancer Immunotherapy Market Size study, By Type (Monoclonal Antibodies, Cancer Vaccines, Checkpoint Inhibitors, Immunomodulators), By Application (Lung Cancer, Breast Cancer, Head and Neck Cancer, Prostate Cancer, Colorectal Cancer, Melanoma, Other

Global Cancer Immunotherapy Market Size study, By Type (Monoclonal Antibodies, Cancer Vaccines, Checkpoint Inhibitors, Immunomodulators), By Application (Lung Cancer, Breast Cancer, Head and Neck Cancer, Prostate Cancer, Colorectal Cancer, Melanoma, Others), By End User (Hospitals, Clinics & Others), and Regional Forecasts 2022-2028

Global Cancer Immunotherapy Market is valued approximately USD 119.31 billion in 2021 and is anticipated to grow with a healthy growth rate of more than 14.0% over the forecast period 2022-2028.

Cancer immunotherapy is a procedure for the stimulation of the immune system to cure cancer and boosts the natural ability to fight against the disease. This therapy is gaining huge traction among the population as it offers long-term cancer protection, has fewer side effects, and cures a variety of cancer. Cancer immunotherapy is adopted in a wide range of cancers such as prostate cancer, lung cancer, colorectal cancer, melanoma, head & neck cancer, breast cancer, and many others. The growing incidences of cancer, increasing development of bioinformatics tools to enhance the drug development process, coupled with the rising adoption of immunotherapy compared to other treatment options are the primary factors that are fostering market growth around the world. For instance, according to the national cancer institute, there were nearly 18.1 million new cases and 9.5 million cancer-associated deaths occurred across the globe in 2018. Moreover, the amount is likely to reach 29.5 million and the number of cancer-associated deaths to 16.4 million by the end of 2040. Thus, the growing occurrence of cancer globally is anticipated to surge the demand for cancer immunotherapy, which, in turn, accelerates the market growth in the near future. However, the availability of limited funds to initiate clinical trials and the high cost of treatment impede the growth of the market over the forecast period of 2022-2028. Also, increasing clinical trials for the treatment of cancers and high growth prospects in emerging nations are anticipated to act as a catalyzing factor for the market demand during the forecast period.

The key regions considered for the Global Cancer Immunotherapy Market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to the rising adoption rate of immunotherapy and increasing investment for the drug development process. Whereas, Asia-Pacific is anticipated to exhibit the highest CAGR over the forecast period 2022-2028. Factors such as the growing presence of the target population, and growth of the emerging economies such as India and China would create lucrative growth prospects for the Cancer Immunotherapy market across the Asia-Pacific region.

Major market players included in this report are:
Amgen, Inc.
Astrazeneca, PLC
F. Hoffmann-La Roche, Ltd. (Genentech, Inc.)
Bayer AG
Eli Lily And Company
Novartis AG
Pfizer, Inc.
Johnson & Johnson (Janssen Global Services, LLC)
Bristol-Myers Squibb Company
Merck KGAA

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Type
Monoclonal Antibodies
Cancer Vaccines
Checkpoint Inhibitors
Immunomodulators
By Application
Lung Cancer
Breast Cancer
Head and Neck Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Others
By End User
Hospitals
Clinics & Others
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028

Target Audience of the Global Cancer Immunotherapy Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors


Companies Mentioned

Amgen, Inc.
Astrazeneca, PLC
F. Hoffmann-La Roche, Ltd. (Genentech, Inc.)
Bayer AG
Eli Lily And Company
Novartis AG
Pfizer, Inc.
Johnson & Johnson (Janssen Global Services, LLC)
Bristol-Myers Squibb Company
Merck KGAA